Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a ...

Consider the following before gently correcting your loved one: The present stage of dementia and your loved one’s ability to process information. Is the behavior connected to dementia, or was it ...

Columnist Ray Burow clarifies some common misconceptions about Alzheimer's disease, particularly that it's a type of mental illness.

Moderate stage Alzheimer's is the second and longest stage of this brain disease, likely marked by increased forgetfulness, confusion, and trouble speaking.

Nearly half of Alzheimer’s disease patients treated with TrueBinding ’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

Blazing through a magazine or newspaper is an activity most of us take for granted. However, someone with cognitive impairment may have difficulty devouring content. Deciphering small print and ...

Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 ...

Read about a clinical trial by Canada's IntelGenx which explores the potential of the old asthma medication montelukast to treat Alzheimer’s disease.

In early-stage Alzheimer's, changes in abilities or behavior may be minor and only noticeable to family and close friends. Some symptoms typify this stage.

Read about a study finding a single, low-dose of methylene blue in healthy people boosted their short-term memory by activating relevant brain regions.